Chronic News and Research

RSS

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

High levels of phosphate in sodas accelerate signs of aging

Here's another reason to kick the soda habit. New research published online in the FASEB Journal shows that high levels of phosphates may add more "pop" to sodas and processed foods than once thought. That's because researchers found that the high levels of phosphates accelerate signs of aging. High phosphate levels may also increase the prevalence and severity of age-related complications, such as chronic kidney disease and cardiovascular calcification, and can also induce severe muscle and skin atrophy.

27 Apr 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, today announced the launch of the DaVita Phosphorus Challenge, an online resource designed to serve as a core learning tool for CKD and dialysis patients.

27 Apr 2010

Laughter increases production of antibodies and activates body's protective cells

Laughter is a highly complex process. Joyous or mirthful laughter is considered a positive stress (eustress) that involves complicated brain activities leading to a positive effect on health. Norman Cousins first suggested the idea that humor and the associated laughter can benefit a person's health in the 1970s. His ground-breaking work, as a layperson diagnosed with an autoimmune disease, documented his use of laughter in treating himself—with medical approval and oversight—into remission.

27 Apr 2010

People infected with gastrointestinal worms respond better to injected vaccines

According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.

27 Apr 2010

Health care costs of abused women change from year to year after abuse ends: Study

Victims of domestic violence endure significantly higher health costs than other women for three years after the abuse ends, a new study finds.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

To help employee members take a more proactive role in managing their own health programs, Avivia Health From Kaiser Permanente today announced the introduction of Your Health Center, a new portal based on Web 2.0 technology that provides user members with powerful digital health coaching and interactive tools. Avivia Health is the only national provider of Wellness and Condition Management Solutions based on 60 years of evidence-based practices by its parent organization, Kaiser Permanente.

27 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

Black children with chronic kidney disease have severe anemia than white children: Study

Black children with chronic kidney disease have more severe anemia than white children even when they receive the same treatment, according to a multicenter study led by Johns Hopkins Children's Center to be published in the May issue of the American Journal of Kidney Disease.

27 Apr 2010

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Phytonutrient intake may help decrease risk for certain chronic diseases: Study

Topping that bowl of cereal with raspberries instead of strawberries, or saut-ing kale instead of spinach for dinner can boost phytonutrient intake, which may help decrease risk for certain chronic diseases, including cardiovascular disease, cancer and diabetes.

27 Apr 2010

Nearly 50% of adult U.S. population at risk from heart disease

The U.S. Centers for Disease Control (CDC) released an alarming new report on Monday. According to the CDC report almost 50% of the adult population of the United States have chronic conditions which could lead to heart disease. The pre-existing diagnosed conditions included high blood pressure, high cholesterol and diabetes.

27 Apr 2010

A first step in the long road to health reform

Australia provides good health care to the majority of its citizens most of the time and compares well with like countries. The capacity for illness to destroy families financially, seen in the US and in many less economically advanced countries where governments make small or no contributions to the cost of health care, is much diminished by Medicare, public hospitals and subsidised pharmaceuticals.

27 Apr 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

Heritage Club Mountain View to host intense competition and educational event

A dynamic culinary competition among area professional senior living chefs highlights healthy cooking, wellness and quality of life for older adults. During the culinary cook-off, the culinary professionals from Brookdale Senior Living, industry-leading owners and operators of senior living communities, will entertain and showcase their culinary talents to compete for the chance to win the "Ultimate Chef America" title.

26 Apr 2010

Chronic News and Research

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

High levels of phosphate in sodas accelerate signs of aging

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

Laughter increases production of antibodies and activates body's protective cells

People infected with gastrointestinal worms respond better to injected vaccines

Health care costs of abused women change from year to year after abuse ends: Study

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Avivia Health announces new portal with digital health coaching and interactive tools for employee members

Tel Aviv University researcher maps drug target to wipe pain away

Black children with chronic kidney disease have severe anemia than white children: Study

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Phytonutrient intake may help decrease risk for certain chronic diseases: Study

Nearly 50% of adult U.S. population at risk from heart disease

A first step in the long road to health reform

Stinging FDA review for Acurox – the implications

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Covidien introduces PENNSAID to the U.S. market

Covidien launches EXALGO Extended-Release Tablets in the US

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Heritage Club Mountain View to host intense competition and educational event

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News